https://www.selleckchem.com/products/OSI-906.html
Hodgkin lymphoma is an aggressive blood cancer that is highly curable in younger patients who receive multiagent chemotherapy. Worse survival in older patients may reflect less-aggressive treatment, competing risks of death, or different disease biological factors. To examine the association between treatment intensity and cause-specific mortality among older adults with Hodgkin lymphoma. This was a population-based cohort study of patients aged 65 years or older with Medicare Part A and B fee-for-service coverage who received a diagnos
Like
Comment
Share
